FDA delays approval of Pfizers maraviroc

Share this article:

The approval of Pfizer's maraviroc was dealt a blow Wednesday as the drug's maker received an approvable letter from the FDA requesting additional information on the investigational HIV compound.

The FDA had been expected to approve maraviroc this week.
 
Pfizer said in a statement, “We plan to continue discussions with the FDA to address any outstanding questions and finalize the product labeling as soon as possible.”

Pfizer did not elaborate on the approvable letter’s questions or issue a timetable for FDA action.

Maraviroc was granted priority review status in February. Priority review status, which trims time off the standard approval time period, is usually granted to compounds deemed an advance over existing therapies by the FDA.

In April, an FDA panel of outside experts recommended the agency approve maraviroc, citing a need for new HIV treatments. However, some panelists shared concerns about liver damage, heart problems and infection associated with the drug. GlaxoSmithKline stopped work on a similar CCR5 drug after it was found to cause liver problems.
 
Analysts have projected sales of maraviroc, if approved, to reach $500 million by 2011.

Share this article:
close

Next Article in News

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.